Proteomic Profiling of Serum Extracellular Vesicles Identifies Diagnostic Signatures and Therapeutic Targets in Breast Cancer
Ganfei Xu,Rui Huang,Reziya Wumaier,Jiacheng Lyu,Minjing Huang,Yaya Zhang,Qingjian Chen,Wenting Liu,Mengyu Tao,Junjian Li,Zhonghua Tao,Bo Yu,Erxiang Xu,Lingfeng Wang,Guoying Yu,Olivier Gires,Lei Zhou,Wei Zhu,Chen Ding,Hongxia Wang
DOI: https://doi.org/10.1158/0008-5472.can-23-3998
IF: 11.2
2024-06-21
Cancer Research
Abstract:Analysis of extracellular vesicles (EVs) is a promising noninvasive liquid biopsy approach for breast cancer (BC) detection, prognosis, and therapeutic monitoring. A comprehensive understanding of the characteristics and proteomic composition of BC-specific EVs from human samples is required to realize the potential of this strategy. In this study, we applied a mass spectrometry-based, data-independent acquisition (DIA) proteomic approach to characterize human serum EVs derived from patients with BC (n = 126) and healthy donors (HDs, n = 70) in a discovery cohort and validated the findings in five independent cohorts. Examination of the EV proteomes enabled construction of specific EV protein classifiers for diagnosing BC and distinguishing patients with metastatic disease. Of note, TALDO1 was found to be an EV biomarker of distant metastasis of BC. In vitro and in vivo analysis confirmed the role of TALDO1 in stimulating BC invasion and metastasis. Finally, high-throughput molecular docking and virtual screening of a library consisting of 271,380 small molecules identified a potent TALDO1 allosteric inhibitor, AO-022, which could inhibit BC migration in vitro and tumor progression in vivo. Together, this work elucidates the proteomic alterations in the serum EVs of BC patients to guide development of improved diagnosis, monitoring, and treatment strategies.
oncology